𝔖 Bobbio Scriptorium
✦   LIBER   ✦

For better or worse: The effect of levodopa on speech in Parkinson's disease

✍ Scribed by Aileen K. Ho; John L. Bradshaw; Robert Iansek


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
168 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

While the beneficial effect of levodopa on traditional motor control tasks have been well documented over the decades, its effect on speech motor control has rarely been objectively examined and the existing literature remains inconclusive. This paper aims to examine the effect of levodopa on speech in patients with Parkinson's disease. It was hypothesized that levodopa would improve preparatory motor set related activity and alleviate hypophonia. Patients fasted and abstained from levodopa overnight. Motor examination and speech testing was performed the following day, pre‐levodopa during their β€œoff” state, then at hourly intervals post‐medication to obtain the best β€œon” state. All speech stimuli showed a consistent tendency for increased loudness and faster rate during the β€œon” state, but this was accompanied by a greater extent of intensity decay. Pitch and articulation remained unchanged. Levodopa effectively upscaled the overall gain setting of vocal amplitude and tempo, similar to its well‐known effect on limb movement. However, unlike limb movement, this effect on the final acoustic product of speech may or may not be advantageous, depending on the existing speech profile of individual patients. Β© 2007 Movement Disorder Society


πŸ“œ SIMILAR VOLUMES


Effects of pallidotomy and levodopa on w
✍ Amy J. Bastian; Valerie E. Kelly; Joel S. Perlmutter; Jonathan W. Mink πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 135 KB πŸ‘ 1 views

## Abstract We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Di

Effects of levodopa and COMT inhibitors
✍ Paolo Lamberti; Stefano Zoccolella; Giovanni Iliceto; Elio Armenise; Angela Frad πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 1 views

## Abstract Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). T

Pattern of subclinical pulmonary dysfunc
✍ Pramod Kumar Pal; Talakad N. Sathyaprabha; Prasad Tuhina; Kandavel Thennarasu πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 106 KB

## Abstract We performed a detailed evaluation of pulmonary function in 53 patients with idiopathic Parkinson's disease (PD) who did not have symptoms of pulmonary or cardiac dysfunction. There was a significant pulmonary dysfunction of restrictive type which partially responded to levodopa. Compar